Life science news and medical media coverage for healthcare professionals
Psychiatry7 Sept 2026
Beyond diabetes: Semaglutide's surprising signal in bipolar disorderRead article
Multicancer early detection: Can we screen for what we can't treat?
An FDA advisory panel has supported the clinical utility of multicancer early detection (MCED) tests, marking a potential shift in cancer screening paradigms.
Why are we still treating cancer prevention as adjunctive care?
Adopting a healthy lifestyle correlates with reduced risk for 13 distinct cancer types, highlighting the role of modifiable factors in oncology.
Breast cancer home injections: Convenient for patients, complex for insurers
Despite the clinical benefits of home-based breast cancer therapy, insurance policies frequently impede patient access to these convenient injection programs.
Brain metastases: Why less radiation, more often, improves outcomes
Lung cancer in never smokers: The 60x risk factor you might be missing
Olaparib: Why HRD in breast and ovarian cancer goes beyond BRCA
Multicancer tests: Can we screen without knowing the outcome?
Chemo hair loss: Why some patients feel it more deeply
Salivary gland cancer: Is HER2-low the new HER2-positive?
ACLF: Why G-CSF works for some, but fails others
Specific immune cell populations and inflammatory markers predict G-CSF treatment response and mortality in acute-on-chronic liver failure, a GRAFT sub-study shows.
MASH: Why diabetes management now demands a liver-first approach?
Emerging liver-directed approaches for moderate to advanced MASH are reshaping treatment paradigms, with significant implications for diabetes specialists managing metabolic dysfunction.
Why primary sclerosing cholangitis remains a therapeutic graveyard
Despite numerous attempts, no disease-modifying therapy has succeeded in primary sclerosing cholangitis, leaving transplant as the only definitive treatment.
Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?
Seladelpar and elafibranor: second-line options for PBC
Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails
Pruritus in primary biliary cholangitis: the symptom that drives quality of life
Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?
Liver disease: Is coffee a daily dose of prevention?
Endocarditis: Why fixed-dose ampicillin often misses the mark
A personalized antibiotic strategy, guided by therapeutic drug monitoring, optimizes ampicillin regimens in enterococcal bloodstream infections and endocarditis.
Tactical athletes need more than a sports physical
New recommendations address cardiovascular screening and management for tactical athletes, focusing on unique physiological demands and risk factors in this population.
GLP-1s: Is eligibility missing half your high-risk patients?
A 313,000-person Danish and UK analysis finds people with a BMI of 25-26.9, currently ineligible for GLP-1 receptor agonists, have coronary heart disease risk matching those who do qualify, if they also carry elevated remnant cholesterol or inflammation.
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Evolocumab: Is LDL-C reduction finally translating to lives saved?
LAA occlusion: Less bleeding, but is stroke risk truly equal?
Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?
Peripheral arterial disease: Why early detection still eludes us
Hypertension: Do shorter wall squats work as well for older women?
The 2026 ADA/EASD consensus: Why early SGLT2/GLP-1 works
The 2026 ADA and EASD consensus advocates early SGLT2 inhibitor or GLP-1-based therapy, potentially from diagnosis, and makes weight a formal treatment target.
Type 1 diabetes screening: Why one protocol worked across 8 nations
EDENT1FI tested 140,568 young people and found early-stage type 1 diabetes in about 1 in 45 with a relative and 1 in 350 without, across 8 countries.
Bariatric surgery: The hidden hernia risk you're missing
Up to 20% of bariatric surgery candidates present with pre-existing ventral hernias, a significant comorbidity often overlooked in surgical planning.
Amylin plus tirzepatide: Is 23% weight loss the new benchmark?
Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?
Survodutide: Is 9.8% weight loss enough for its GI cost?
Marathon running with type 1 diabetes: Is it finally safe?
CBL-514: Is visceral fat reduction the real story?
Low-carb diets in kids with type 1 diabetes: safe, but not standard?
Epilepsy: Is art the missing piece in holistic patient care?
A new exhibit showcases artists living with epilepsy, aiming to reframe public perception of the condition beyond its clinical manifestations.
Lifelong odor sensitivity: What early exposure means for your patients?
Early-life exposure to specific odors permanently suppresses an odor processing channel in Drosophila, demonstrating lifelong changes to odor sensitivity via glial pruning.
Fibromyalgia: Is the pain real if the tissue damage isn't?
Fibromyalgia is increasingly understood as a central nervous system disorder, not a peripheral tissue disease, challenging traditional diagnostic approaches.
Tau: Why its 'knockout' effect is a clue to Alzheimer's
Routine childhood vaccines: Less coverage means more than just infections
Can mice learn to control their own brains? A new neurofeedback system
Brexpiprazole for Alzheimer's agitation: Antidepressants don't change efficacy
Spike sorting: Is your 'black box' holding back neural insights?
Parkinson's cognitive decline: Is Juvmo the answer we overlooked?
R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end
An epidemiological shift in T2D is reshaping drug development and market access for oncology and metabolic portfolios.
The most resistant cancer is finally responding, and the pipeline is accelerating
Lecanemab and donanemab are approved. The harder question is who gets them and how
Label expansion triples the eligible population and the infrastructure race begins
LeukemiaRusfertide and hepcidin mimetics: a different way to control erythrocytosis
Get the full storyHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full storyGene therapy for thalassemia: Approval is one hurdle, access is the next
Get the full story
Idiopathic Pulmonary Fibrosis
Clostridioides difficile
Advertisement
• Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US 
• Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12LIVEUEG Week 2026 • Barcelona, ES • Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US • Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12AdvertisementAdvertisement
Advertisement
BarcelonaOct 17 – 20 2026Get on-site reporting the moment it publishes.
BarcelonaAttending UEG Week 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
